Clover Biopharmaceuticals, Ltd. disclosed minimal equity movement in its Monthly Return for the period ended 31 October 2026. The company issued 5,000 new ordinary shares, taking total issued share capital to 1.30 billion shares. Treasury share balance remained at zero.
The additional shares stemmed from option exercises under the Post-IPO Share Option Plan, which saw 5,000 options converted and 75,000 options lapse. Outstanding options under this scheme declined to 42.04 million, while the Pre-IPO Share Option Plan held steady at 1.34 million outstanding options. Proceeds from option exercises amounted to HKD 1.21 thousand.
Authorised share capital was unchanged at 2.00 billion ordinary shares with a par value of USD 0.0001, representing total authorised capital of USD 200,000. The company confirmed that it continued to meet the Hong Kong Stock Exchange’s minimum 25% public-float requirement.
No movements were recorded in treasury shares, warrants, convertible securities, or other share-issuance arrangements during the month.
Comments